G62.8
Conditions
Interventions
Group 1: Patients who developed an intensive care unit aquired weakness after critical illness and who do not require analgosedation. Timepoint of measurement normally would be briefly prior to discha
Sponsors
Universitätsmedizin Göttingen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Signed informed consent (by participant or legal guardian)
Exclusion criteria
Exclusion criteria: - acute or chronic severe neurological disease (progressive dementia, degenerative disease of the central nervous system) - Diseases of the optic system (e.g. glaucoma, macula degeneration, macula degeneration, cerebral infarction of parts of the optic tracts and radiation) - Current treatment with centrally acting medication with effects on the pupillary light reaction (e.g. opioids and porpofol) Current treatment with medication directly modifying the pupillary light reaction (medication with mydriatic effects, medication with miotic effects (e.g. parasympathmimetic medication)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Latency of the pupillary light reflex as measured by an electronic pupillometer (PLR-3000 Pupillometer); once, after the critical phase of the main acute disease | — |
Secondary
| Measure | Time frame |
|---|---|
| - Amplitude of the pupillary light reflex - Velocity of the pupillary light reflex as measured by an electronic pupillometer each (PLR-3000 Pupillometer) | — |
Countries
Germany
Contacts
Public ContactCaspar Stephani
Universitätsmedizin Göttingen
Outcome results
None listed